Jeffrey J. Raizer

13.2k total citations · 1 hit paper
175 papers, 6.2k citations indexed

About

Jeffrey J. Raizer is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Jeffrey J. Raizer has authored 175 papers receiving a total of 6.2k indexed citations (citations by other indexed papers that have themselves been cited), including 111 papers in Genetics, 70 papers in Pulmonary and Respiratory Medicine and 49 papers in Oncology. Recurrent topics in Jeffrey J. Raizer's work include Glioma Diagnosis and Treatment (109 papers), Brain Metastases and Treatment (56 papers) and Meningioma and schwannoma management (24 papers). Jeffrey J. Raizer is often cited by papers focused on Glioma Diagnosis and Treatment (109 papers), Brain Metastases and Treatment (56 papers) and Meningioma and schwannoma management (24 papers). Jeffrey J. Raizer collaborates with scholars based in United States, Canada and Germany. Jeffrey J. Raizer's co-authors include Lauren E. Abrey, Patrick Y. Wen, Lisa M. DeAngelis, Sean Grimm, Timothy F. Cloughesy, David Schiff, Mark H. Bilsky, Eric Lis, James P. Chandler and Patrick J. Boland and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Jeffrey J. Raizer

170 papers receiving 6.1k citations

Hit Papers

NRG Oncology/RTOG1205: A Randomized Phase II Trial of Con... 2022 2026 2023 2024 2022 25 50 75 100
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma
    2022 104 citations Christina Tsien, Stephanie L. Pugh et al. Journal of Clinical Oncology profile →

Peers

Jeffrey J. Raizer
Patrick Roth Switzerland
Philippe Métellus France
Jan Drappatz United States
Uri Tabori Canada
Lakshmi Nayak United States
Mehar Chand Sharma India
John L. Villano United States
Ulrich Herrlinger Germany
Didier Frappaz France
Fábio M. Iwamoto United States
Patrick Roth Switzerland
Jeffrey J. Raizer
Citations per year, relative to Jeffrey J. Raizer Jeffrey J. Raizer (= 1×) peers Patrick Roth

Countries citing papers authored by Jeffrey J. Raizer

Since Specialization
Citations

This map shows the geographic impact of Jeffrey J. Raizer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey J. Raizer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey J. Raizer more than expected).

Fields of papers citing papers by Jeffrey J. Raizer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey J. Raizer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey J. Raizer. The network helps show where Jeffrey J. Raizer may publish in the future.

Co-authorship network of co-authors of Jeffrey J. Raizer

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey J. Raizer. A scholar is included among the top collaborators of Jeffrey J. Raizer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey J. Raizer. Jeffrey J. Raizer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gao, Xiang, Anthony J. Olszanski, Gerald S. Falchook, et al.. (2024). 996MO Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced/metastatic solid tumors: Data from phase I dose escalation. Annals of Oncology. 35. S678–S679. 1 indexed citations
2.
Klempner, Samuel J., Keun‐Wook Lee, Kohei Shitara, et al.. (2023). ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2–Positive Gastric or Gastroesophageal Junction Adenocarcinoma. Clinical Cancer Research. 29(19). 3882–3891. 44 indexed citations
3.
Tsien, Christina, Stephanie L. Pugh, Adam P. Dicker, et al.. (2022). NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma. Journal of Clinical Oncology. 41(6). 1285–1295. 104 indexed citations breakdown →
4.
5.
Malani, Rachna, Martin Fleisher, Priya Kumthekar, et al.. (2020). Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer. Journal of Neuro-Oncology. 148(3). 599–606. 62 indexed citations
6.
Raizer, Jeffrey J., Karen Fitzner, Daniel I. Jacobs, et al.. (2015). Economics of Malignant Gliomas: A Critical Review. Journal of Oncology Practice. 11(1). e59–e65. 47 indexed citations
7.
Curry, Richard, Saurabh Dahiya, Vyshak Alva Venur, Jeffrey J. Raizer, & Manmeet S. Ahluwalia. (2015). Bevacizumab in high-grade gliomas: past, present, and future. Expert Review of Anticancer Therapy. 15(4). 387–397. 18 indexed citations
8.
Yoshida, Yasuyuki, Tomoko Ozawa, Shen Wang, et al.. (2014). NT113, a Pan-ERBB Inhibitor with High Brain Penetrance, Inhibits the Growth of Glioblastoma Xenografts with EGFR Amplification. Molecular Cancer Therapeutics. 13(12). 2919–2929. 15 indexed citations
9.
10.
Reardon, David A., Morris D. Groves, Patrick Y. Wen, et al.. (2013). A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma. Clinical Cancer Research. 19(4). 900–908. 91 indexed citations
11.
Morris, Patrick G., Denise D. Correa, Joachim Yahalom, et al.. (2013). Rituximab, Methotrexate, Procarbazine, and Vincristine Followed by Consolidation Reduced-Dose Whole-Brain Radiotherapy and Cytarabine in Newly Diagnosed Primary CNS Lymphoma: Final Results and Long-Term Outcome. Journal of Clinical Oncology. 31(31). 3971–3979. 316 indexed citations
12.
Shirazi, Haider, Sean Grimm, Jeffrey J. Raizer, & Minesh P. Mehta. (2011). Combined Modality Approaches in the Management of Adult Glioblastoma. SHILAP Revista de lepidopterología. 1. 36–36. 8 indexed citations
13.
DeBoer, Rebecca, H. Hunt Batjer, Maryanne H. Marymont, et al.. (2009). Response of an adult patient with pineoblastoma to vorinostat and retinoic acid. Journal of Neuro-Oncology. 95(2). 289–292. 8 indexed citations
14.
Carroll, Timothy J., et al.. (2008). Quantification of cerebral perfusion using the “bookend technique”: an evaluation in CNS tumors. Magnetic Resonance Imaging. 26(10). 1352–1359. 38 indexed citations
15.
Das, Sunit, Kenji Muro, & Jeffrey J. Raizer. (2007). Surgery for Brain Metastases. Cancer treatment and research. 136. 75–90. 2 indexed citations
16.
Omuro, Antonio, Jeffrey J. Raizer, Alexis Demopoulos, Mark G. Malkin, & Lauren E. Abrey. (2006). Vinorelbine combined with a protracted course of temozolomide for recurrent brain Metastases: a phase I trial. Journal of Neuro-Oncology. 78(3). 277–280. 42 indexed citations
17.
Raizer, Jeffrey J., Jason A. Koutcher, Lauren E. Abrey, et al.. (2005). Proton magnetic resonance spectroscopy in immunocompetent patients with primary central nervous system lymphoma. Journal of Neuro-Oncology. 71(2). 173–180. 36 indexed citations
18.
Chang, Susan M., Patrick Y. Wen, Timothy F. Cloughesy, et al.. (2005). Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Investigational New Drugs. 23(4). 357–361. 308 indexed citations
19.
Liberato, Bernardo, et al.. (2003). Myelopathy from Waldenström's macroglobulinemia: improvement after Rituximab therapy. Journal of Neuro-Oncology. 63(2). 207–211. 11 indexed citations
20.
Holder, Mark D., Raz Yirmiya, John García, & Jeffrey J. Raizer. (1989). Conditioned taste aversions are not readily disrupted by external excitation.. Behavioral Neuroscience. 103(3). 605–611. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Patrick Roth Breakdown of academic impact, for papers by Philippe Métellus Breakdown of academic impact, for papers by Jan Drappatz Breakdown of academic impact, for papers by Uri Tabori Breakdown of academic impact, for papers by Lakshmi Nayak Breakdown of academic impact, for papers by Mehar Chand Sharma Breakdown of academic impact, for papers by John L. Villano Breakdown of academic impact, for papers by Ulrich Herrlinger Breakdown of academic impact, for papers by Didier Frappaz Breakdown of academic impact, for papers by Fábio M. Iwamoto
Rankless by CCL
2026